First Patient Enrolled in European-Wide Observational Study on Liver Cancer Treatment with SIR-SPHERES Microspheres

Monday 19 January 2015
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched its CIRSE Registry for SIR-Spheres Therapy (CIRT), a new European-wide observational study that will gather data on patients with primary and secondary liver tumours treated with SIR-Spheres microspheres at specialist hospitals across Europe.

Austria, Vienna, 19 January 2015 – The European-wide observational study on the treatment of primary and secondary liver tumours with SIR-Spheres microspheres has been designed to collect large amount of data on the real-life application of Selective Internal Radiation Therapy (SIRT), also known as radioembolisation. Furthermore, the study collects extensive quality-of-life data to learn more about the palliative aspect of SIR-Spheres microspheres. CIRT is a single device registry that was developed by the Society in collaboration with Sirtex Medical, the manufacturer of SIR-Spheres Y-90 resin microspheres. Previous research on SIR-Spheres microspheres has shown positive results in the treatment of liver cancer.

Professor José Ignacio Bilbao, speaking on behalf of CIRSE as Chairman of the CIRT Steering Committee, stated that ”CIRSE is pleased to have developed the CIRT registry, which we believe will help the doctors who administer SIR-Spheres therapy to understand better the real-life clinical application of SIR-Spheres microspheres throughout Europe”. He added that “our goal is to enter treatment data on over 500 patients a year from more than 20 specialist European hospitals into the new CIRT registry.” Professor

Bilbao is head of interventional radiology at Clínica Universidad de Navarra in Pamplona, Spain.

About CIRSE:

CIRSE is a non-profit, educational and scientific association aiming to improve patient care through the support of teaching, science, research and clinical practice in the field of cardiovascular and

interventional radiology. CIRT is the largest observational study run exclusively by CIRSE.


For further information on the CIRT study, please contact:

Niels de Jong; CIRSE, +43 1 904 2003 47,, or visit

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage